Chronic Hand Eczema (CHE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Chronic Hand Eczema (CHE) encompasses either a persistent, recurring manifestation of hand eczema (HE) enduring beyond three months or HE resistant to conventional treatment with emollients and topical corticosteroids, characterized by symptoms recurring twice yearly despite intervention. Clinical manifestations of CHE include typical eczema features localized to the hands and fingers, such as dryness, redness, swelling, thickening of the skin, flaking, hardening, roughness, blistering, cracking, itching, and discomfort. Hand eczema can be broadly classified into three primary etiological categories: irritant contact dermatitis (ICD), allergic contact dermatitis (ACD), and atopic hand eczema, constituting more than half of all cases. Eczema and dermatitis are used interchangeably to denote a specific inflammatory condition affecting the epidermis and dermis of the skin. Acute and subacute HE denotes eczematous changes confined to the hands, persisting for less than three months and occurring no more than once annually. In the acute phase, vesicles are commonly present, though not universally, in irritant HE. Erythema, indicative of inflammation, is prominent in acute HE, alongside swelling. Burning and itching sensations are subjectively reported in most instances. Chronic HE refers to an ongoing eczematous process exceeding three months in duration or recurring at least twice annually. Scaling and fissuring are prevalent features, with hyperkeratosis observed in chronic irritant and allergic HE, as well as in endogenous hyperkeratotic HE and other persistent cases. There exists a significant therapeutic gap for effectively managing CHE long-term, particularly in moderate-to-severe instances, with no FDA-approved treatments currently available for chronic hand eczema. Delgocitinib, a JAK-inhibitor cream developed by Leo Pharma, has obtained fast-track designation from the U.S. Food and Drug Administration (FDA) for chronic hand eczema, offering potential promise in addressing this unmet need.

 

Thelansis’s “Chronic Hand Eczema (CHE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Hand Eczema (CHE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Chronic Hand Eczema (CHE) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic Hand Eczema (CHE) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Chronic Hand Eczema (CHE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Chronic Hand Eczema (CHE), Chronic Hand Eczema (CHE) market outlook, Chronic Hand Eczema (CHE) competitive landscape, Chronic Hand Eczema (CHE) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)